AMAG Pharmaceuticals, Inc. Announces Fourth Quarter and Year End 2011 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. As of December 31, 2011, the company’s cash, cash equivalents and investments totaled approximately $230 million.